D Rhamnose β‑Hederin against human breast cancer by reducing tumor‑derived exosomes

Chen, Weixian; Cheng, Lin; Pan, Meng; Qian, Qi; Zhu, Yuan Xiao; Xu, Lingyun; Ding, Qiang

doi:10.3892/ol.2018.9254

Cited by 16 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…D Rhamnose β-hederin (DRβ-H), a triterpenoid saponin, could reduce the growth and apoptosis of cancer cells by inhibiting the secretion process of exosomes. Subsequently, some specifically encapsulated miRNAs, including miR-130a and miR-425, were also downregulated [114]. Shikonin (SK) could also suppress exosome release accompanying with reduced miR-128 [115] and restrain the cancer-promoting effects of preadipocytes through disturbing miR-140/SOX9 signaling [116].…”

Section: Therapeutic Methods Targeting At the Exosomal Micrornasmentioning

confidence: 99%

The Role of Exosomal MicroRNAs in the Tumor Microenvironment of Breast Cancer

Liu

Peng

Chen

2019

IJMS

View full text Add to dashboard Cite

Breast cancer, ranking first among women’s cancers worldwide, develops from the breast tissue. Study of the breast tissue is, therefore of great significance to the diagnosis and treatment of breast cancer. Exosomes, acting as an effective communicator between cells, are in the ascendant in recent years. One of the most important cargoes contained in the exosomes is microRNAs, belonging to the non-coding RNA family. When the exosomal microRNAs are absorbed into the intracellular location, most of the microRNAs will act as tumor promoters or suppressors by inhibiting the translation process of the target mRNA, thus affecting the behavior of other stromal cells in the tumor microenvironment. At present, growing research focuses on the different types of donor cell sources, their contribution to cancer, miRNA profiling, their biomarker potential, etc. This review aims to state the function of diverse miRNAs in exosomes medicated cell–cell communication and the potency of some specific enriched miRNAs as molecular markers in clinical trials. We also describe the mechanism of anti-cancer compounds through exosomes and the exploration of artificially engineered techniques that lead miRNA-inhibitors into exosomes for therapeutic use.

show abstract

Section: Therapeutic Methods Targeting At the Exosomal Micrornasmentioning

confidence: 99%

The Role of Exosomal MicroRNAs in the Tumor Microenvironment of Breast Cancer

Liu

Peng

Chen

2019

IJMS

View full text Add to dashboard Cite

show abstract

“…However, it has been recently suggested that miRNA biosynthesis can occur in extracellular vesicles in breast cancer [ 168 ], providing a new level of complexity. In either case, treatment with compounds that stop this process can prevent breast cancer progression by reducing miRNA-derived extracellular vesicles [ 169 , 170 ]. CSCs also secrete miRNAs in extracellular vesicles [ 171 ], suggesting that the successful treatment of breast cancer may lie in the ability to stop the secretion of extracellular vesicles containing miRNAs.…”

Section: Use Of Mirnas As Biomarkers For Breast Cancermentioning

confidence: 99%

MicroRNA Regulation of Breast Cancer Stemness

Humphries

Wang

Yang

2021

IJMS

View full text Add to dashboard Cite

Recent advances in our understanding of breast cancer have demonstrated that cancer stem-like cells (CSCs, also known as tumor-initiating cell (TICs)) are central for progression and recurrence. CSCs are a small subpopulation of cells present in breast tumors that contribute to growth, metastasis, therapy resistance, and recurrence, leading to poor clinical outcome. Data have shown that cancer cells can gain characteristics of CSCs, or stemness, through alterations in key signaling pathways. The dysregulation of miRNA expression and signaling have been well-documented in cancer, and recent studies have shown that miRNAs are associated with breast cancer initiation, progression, and recurrence through regulating CSC characteristics. More specifically, miRNAs directly target central signaling nodes within pathways that can drive the formation, maintenance, and even inhibition of the CSC population. This review aims to summarize these research findings specifically in the context of breast cancer. This review also discusses miRNAs as biomarkers and promising clinical therapeutics, and presents a comprehensive summary of currently validated targets involved in CSC-specific signaling pathways in breast cancer.

show abstract

“…D Rhamnose β-hederin from the vine Clematis ganpiniana (H.Lév. and Vaniot) Tamura reduced breast cancer tumor cell exosome production, exosomes which either carry genetic cargo coding for Docetaxel chemoresistance ( Chen et al, 2018b ) or simply pro-metastatic miRNAs, like miR-130 and miR-425 ( Chen et al, 2018a ). Finally, in breast cancer cell lines, Timosaponin A-III, extracted from the plant species Anemarrhena asphodeloides Bunge, has been shown to induce the expression of miR-200c and miR-141, both of which may target c-Myc.…”

Section: Terpenoids and Meroterpenoidsmentioning

confidence: 99%

Two Worlds Colliding: The Interplay Between Natural Compounds and Non-Coding Transcripts in Cancer Therapy

et al. 2021

View full text Add to dashboard Cite

Cancer is a devastating disease and has recently become the leading cause of death in western countries, representing an immense public health burden. When it comes to cancer treatment, chemotherapy is one of the main pillars, especially for advanced stage tumors. Over the years, natural compounds have emerged as one of the most valuable resources for new chemotherapies. It is estimated that more than half of the currently used chemotherapeutic agents are derived from natural compounds. Usually, natural compounds are discovered empirically and an important limitation of introducing new anti-cancer natural products is lack of knowledge with regard to their mechanism of action. Recent data has proven that several natural compounds may function via modulating the expression and function of non-coding RNAs (ncRNAs). NcRNAs are a heterogenous class of RNA molecules which are usually not translated into proteins but have an important role in gene expression regulation and are involved in multiple tumorigenic processes, including response/resistance to pharmacotherapy. In this review, we will discuss how natural compounds function via ncRNAs while summarizing the available data regarding their effects on over 15 types of cancer. Moreover, we will critically analyze the current advances and limitations in understanding the way natural compounds exert these health-promoting effects by acting on ncRNAs. Finally, we will propose several hypotheses that may open new avenues and perspectives regarding the interaction between natural compounds and ncRNAs, which could lead to improved natural compound-based therapeutic strategies in cancer.

show abstract

D Rhamnose β‑Hederin against human breast cancer by reducing tumor‑derived exosomes

Cited by 16 publications

References 29 publications

The Role of Exosomal MicroRNAs in the Tumor Microenvironment of Breast Cancer

The Role of Exosomal MicroRNAs in the Tumor Microenvironment of Breast Cancer

MicroRNA Regulation of Breast Cancer Stemness

Two Worlds Colliding: The Interplay Between Natural Compounds and Non-Coding Transcripts in Cancer Therapy

Contact Info

Product

Resources

About